Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Control: Journal of the Moffitt Cancer Cente

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/107327480901600204PMID 19337198
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors

  2008cited by this paper
• Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

  2008cited by this paper
• Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

  2008cited by this paper
• molecule Beyond the increasing complexity of the immunomodulatory HLA-G

  2008cited by this paper
• Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

  2008cited by this paper
• Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia.

  2007cited by this paper
• IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

  2007cited by this paper
• Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

  2007cited by this paper
• Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

  2007cited by this paper
• Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

  2007cited by this paper
• Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

  2007cited by this paper
• Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

  2007cited by this paper
• Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

  2007cited by this paper
• Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements

  2007cited by this paper
• Effect of Cellular Quiescence on the Success of Targeted CML Therapy

  2007cited by this paper
• DNA-Based Measurement of BCR-ABL in Chronic Myeloid Leukemia (CML).

  2007cited by this paper
• Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

  2006cited by this paper
• Chronic myeloid leukemia: diagnosis and treatment.

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2006cited by this paper
• Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications

  2006cited by this paper
• Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

  2006cited by this paper
• Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

  2006cited by this paper
• The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

  2006cited by this paper
• Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

  2006cited by this paper
• Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.

  2006cited by this paper
• Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

  2006cited by this paper
• Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.

  2006cited by this paper
• AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

  2006cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

  2005cited by this paper
• High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

  2005cited by this paper
• Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.

  2005cited by this paper
• hOCT 1 and resistance to imatinib.

  2005cited by this paper
• Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

  2005cited by this paper
• Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

  2005cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• Dynamics of chronic myeloid leukaemia

  2005cited by this paper
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

  2005cited by this paper
• Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

  2005cited by this paper
• Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

  2005cited by this paper
• Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

  2004cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

  2004cited by this paper
• Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

  2004cited by this paper
• Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.

  2004cited by this paper
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

  2004cited by this paper
• Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588

  2004cited by this paper
• The biology of CML blast crisis.

  2004cited by this paper
• A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2*

  2004cited by this paper
• Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

  2004cited by this paper
• Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors

  2004cited by this paper
• Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

  2004cited by this paper
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.

  2003cited by this paper
• Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

  2003cited by this paper
• MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

  2003cited by this paper
• Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

  2003cited by this paper
• Minimal residual disease in chronic myeloid leukemia.

  2003cited by this paper
• Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.

  2003cited by this paper
• The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

  2003cited by this paper
• Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

  2003cited by this paper
• A myristoyl/phosphotyrosine switch regulates c-Abl.

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

  2003cited by this paper
• Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

  2003cited by this paper
• Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux

  2003cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.

  2002cited by this paper
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia

  2002cited by this paper
• Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

  2002cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

  2001cited by this paper
• The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

  2001cited by this paper
• A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.

  2001cited by this paper
• Src family tyrosine kinases and growth factor signaling.

  2000cited by this paper
• Role of 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI 571

  2000cited by this paper
• Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

  2000cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells

  1999cited by this paper
• Cell cycle targets of Ras/Raf signalling

  1998cited by this paper
• Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.

  1998cited by this paper
• Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

  1998cited by this paper
• c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia.

  1998cited by this paper
• Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

  1997cited by this paper
• Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.

  1995cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

  1984cited by this paper
• Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

  1983cited by this paper

• Raman spectroscopy studies on imatinib sensitive and resistant chronic myeloid leukemia cells

  2025cites this paper
• Mechanism of Chemotherapy Resistance: a Comprehensive Review

  2025cites this paper
• P28-19 Dasatinib decreases male gernline stem cell colony growth in vitro, but do not induce apoptosis in germ cells with clinically relevant doses ex vivo

  2025cites this paper
• Synergistic Inhibition of Chronic Myeloid Leukemia: Combining Imatinib and Naringin to Overcome Drug Resistance

  2025cites this paper
• Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias

  2025cites this paper
• ZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming

  2025cites this paper
• CRISPR Technology: Transforming the Future of Medicine and Diagnostics

  2025cites this paper
• ERRATUM: Synergistic Inhibition of Chronic Myeloid Leukemia: Combining Imatinib and Naringin to Overcome Drug Resistance

  2025cites this paper
• Polymer-Based Antimicrobial Peptide Mimetics for Treating Multi-drug Resistant Infections: Therapy and Toxicity Evaluation

  2024cites this paper
• Exploring the Dark Matter of Human Proteome: The Emerging Role of Non-Canonical Open Reading Frame (ncORF) in Cancer Diagnosis, Biology, and Therapy

  2024cites this paper
• The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance.

  2024cites this paper
• Overcoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers.

  2024cites this paper
• Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia

  2024cites this paper
• Imatinib decreases germ cell survival and germline stem cell proliferation in rodent testis ex vivo and in vitro

  2024cites this paper
• The role of m6A methylation in therapy resistance in cancer

  2023influential citation
• Effects of

  2023cites this paper
• Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

  2023cites this paper
• Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years

  2023cites this paper
• Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies

  2023cites this paper
• Cancer Chemoresistance; Recent Challenges and Future Considerations.

  2023cites this paper
• A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy

  2022cites this paper
• Dynein axonemal heavy chain 9 M4374I variation may have an effect on imatinib mesylate resistance in CML

  2022cites this paper
• Laboratory Techniques in Cellular and Molecular Medicine

  2022cites this paper
• Developing therapeutic approaches for chronic myeloid leukemia: a review

  2022cites this paper
• Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.

  2022cites this paper
• Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells

  2022cites this paper
• Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial

  2022cites this paper
• Drug Targeting and Therapeutic Management of Chronic Myeloid Leukemia: Conventional and Nanotherapeutic Drug Options.

  2022cites this paper
• Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies

  2022cites this paper
• Evaluation of the combined effect of naringin and imatinib in philadelphia positive chronic myeloid leukemia

  2022cites this paper
• Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer.

  2022cites this paper
• Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches

  2022cites this paper
• A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients

  2022cites this paper
• KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia

  2021cites this paper
• PKC‐β/Alox5 axis activation promotes Bcr‐Abl‐independent TKI‐resistance in chronic myeloid leukemia

  2021cites this paper
• Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review

  2021cites this paper
• MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate

  2021cites this paper
• DNA Fingerprint Analysis of Raman Spectra Captures Global Genomic Alterations in Imatinib-Resistant Chronic Myeloid Leukemia: A Potential Single Assay for Screening Imatinib Resistance

  2021cites this paper
• Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations

  2021cites this paper
• Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.

  2021cites this paper
• JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.

  2021influential citation
• H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report.

  2021cites this paper
• Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining

  2021cites this paper
• Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib

  2021cites this paper
• Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity

  2021cites this paper
• ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells.

  2021cites this paper
• Molecular and cellular paradigms of multidrug resistance in cancer

  2020cites this paper
• Overexpression of P‐glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients

  2020cites this paper
• Involvement of Oxidative Stress in Resistance to Tyrosine-Kinase Inhibitors Therapy in Chronic Myeloid Leukemia

  2020cites this paper
• Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line

  2020cites this paper
• Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.

  2020cites this paper
• Chronic Myeloid Leukemia

  2020cites this paper
• Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications.

  2020cites this paper
• ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ ПОЛИМОРФНЫХ ВАРИАНТОВ ГЕНОВ CYP3A5 И hOCT1 У БОЛЬНЫХ ХРОНИЧЕСКИМ МИЕЛОЛЕЙКОЗОМ В РЕСПУБЛИКЕ БАШКОРТОСТАН

  2019cites this paper
• Decreased expression of microRNA-451 is associated with imatinib mesylate resistance in patients with chronic myeloid leukemia

  2019cites this paper
• Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.

  2019cites this paper
• Andrographolide and its potent derivative exhibit anticancer effects against imatinib‐resistant chronic myeloid leukemia cells by downregulating the Bcr‐Abl oncoprotein

  2019cites this paper
• Lack of association between functional polymorphism of DNA repair genes (XRCC1, XPD) and clinical response in Indian chronic myeloid leukemia patients

  2019cites this paper
• Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia.

  2019cites this paper
• Drug resistance and combating drug resistance in cancer

  2019cites this paper
• A novel in-frame 231bp deletion mutation in ABL1 kinase activation loop

  2019cites this paper
• PROGNOSTIC VALUE OF CYP3A5 AND hOCT1 POLYMORPHIC GENE VARIANTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE REPUBLIC OF BASHKORTOSTAN

  2019cites this paper
• Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

  2019cites this paper
• Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments.

  2019cites this paper
• CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES

  2019cites this paper
• Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

  2019cites this paper
• Alkynylnicotinamide‐Based Compounds as ABL1 Inhibitors with Potent Activities against Drug‐Resistant CML Harboring ABL1(T315I) Mutant Kinase

  2018cites this paper
• Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing

  2018influential citation
• Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C→A) of Bcr/Abl gene in a chronic myeloid leukemia patient.

  2018cites this paper
• The underestimated role of basophils in Ph+ chronic myeloid leukaemia

  2018cites this paper
• Targeting autophagy in chronic myeloid leukemia through inhibition of the core autophagy protein ATG4B

  2018cites this paper
• Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-α-mediated G2/M phase arrest in chronic myeloid leukaemia

  2018cites this paper
• Alterations in WNT Signaling in Leukemias

  2018cites this paper
• Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients

  2018cites this paper
• Early Predictors of Suboptimal Response to CML Therapy Could Help in Determining Treatment Strategy

  2018cites this paper
• Chronic Myeloid Leukemia: Beyond BCR-ABL1

  2018cites this paper
• Roles of endoplasmic reticulum stress and autophagy on H2O2-induced oxidative stress injury in HepG2 cells

  2018cites this paper
• Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant

  2018cites this paper
• PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β

  2017cites this paper
• Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines

  2017cites this paper
• Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia

  2017cites this paper
• Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

  2017cites this paper
• UNIVERSITY OF NAPLES "FEDERICO II" Doctorate School in Advanced Medical and Surgical Therapies XXIX Cycle

  2017cites this paper
• IMPACT OF T315I MUTATION ON THE OUTCOME OF IMATINIB-RESISTANT CML IN EGYPTIAN PATIENTS.

  2017cites this paper
• An investigation of metabolic vulnerabilities in chronic myeloid leukaemic stem cells

  2017influential citation
• Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

  2017cites this paper
• Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia

  2017cites this paper
• SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment

  2017cites this paper
• Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib

  2017cites this paper
• The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor

  2017cites this paper
• Cephalotaxus Alkaloids

  2017cites this paper
• Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq

  2017cites this paper
• Batch Effect Detection and Network Analysis in BCR/ABL-independent CML Imatinib Resistance

  2017cites this paper
• Indomethacin enhances the sensitivity of CD 34 + phase chronic myeloid leukemia

  2016cites this paper
• New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.

  2016cites this paper
• Second- and third-generation ALK inhibitors for non-small cell lung cancer

  2016cites this paper
• High-Throughput Screening of Tyrosine Kinase Inhibitor Resistant Genes in CML.

  2016cites this paper
• A New Mutation Identified in an Imatinib and Nilotinib Resistant ChronicMyeloid Leukemia Patient

  2016cites this paper
• Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia

  2016cites this paper
• Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies

  2016cites this paper